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Abstract
Background: The STAT (Signal Transducers and Activators of Transcription) transcription factor family
mediates cellular responses to a wide range of cytokines. Activated STATs (particularly STAT3) are found
in a range of cancers. Further, STAT3 has anti-apoptotic functions in a range of tumour cell lines. After
observing a proteolytic cleavage in STAT3α close to a potential apoptotic caspase protease cleavage site
we investigated whether STAT3α might be a caspase substrate.
Methods: STAT3α status was investigated in vitro in several cell systems:- HM-1 murine embryonic stem
(ES) cells following various interventions; IOUD2 murine ES cells following induction to differentiate along
neural or adipocyte lineages; and in a number of breast cancer cell lines. STAT3α status was also analysed
in vivo in wild type murine mammary glands undergoing controlled, forced involution.
Results: Immunoblotting for STAT3α in HM-1 ES cell extracts detected amino and carboxy terminal
species of approximately 48 kDa and 43 kDa respectively – which could be diminished dose-dependently
by cell treatment with the nitric oxide (NO) donor drug sodium nitroprusside (SNP). UV irradiation of
HM-1 ES cells triggered the STAT3α cleavage (close to a potential caspase protease cleavage site).
Interestingly, the pan-caspase inhibitor z-Val-Ala-DL-Asp-fluoromethylketone (z-VAD-FMK) and the JAK2
tyrosine kinase inhibitor AG490 both inhibited cleavage dose-dependently, and cleavage was significantly
lower in a heterozygous JAK2 knockout ES cell clone. STAT3α cleavage also occurred in vivo in normal
murine mammary glands undergoing forced involution, coinciding with a pulse of phosphorylation of
residue Y705 on full-length STAT3α. Cleavage also occurred during IOUD2 ES cell differentiation (most
strikingly along the neural lineage) and in several human breast cancer cell lines, correlating strongly with
Y705 phosphorylation.
Conclusion: This study documents a proteolytic cleavage of STAT3α into 48 kDa amino and 43 kDa
carboxyl terminal fragments in a range of cell types. STAT3α cleavage occurs close to a potential caspase
site, and can be inhibited dose-dependently by SNP, AG490 and z-VAD-FMK. The cleavage seems to be
caspase-dependent and requires the phosphorylation of STAT3α at the Y705 residue. This highly regulated
STAT3α cleavage may play an important role in modulating STAT3 transcriptional activity.
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Background
The STAT (Signal Transducers and Activators of Transcrip-
tion) transcription factor and JAK protein tyrosine kinase
families mediate the responses of eukaryotic cells to a
wide range of cytokine molecules [1-6]. Classically, upon
binding a cytokine ligand, the dimerization or oligomeri-
zation of receptor components occurs, with receptor-asso-
ciated JAK protein tyrosine kinases now able to
reciprocally phosphorylate each other, leading to a tyro-
sine phosphorylation of the receptor cytoplasmic region.
Recognition of this receptor phosphotyrosine residue by
the SH2 domain of STAT proteins allows the association
of STAT proteins with the receptor complex. The subse-
quent tyrosine phosphorylation of STAT proteins (at resi-
due Y705 for STAT3) induces dimerization, nuclear
translocation and DNA binding to recognition sequences
in target gene promoters.
STAT3 cDNAs were originally cloned from murine sources
[7-9], the encoded protein was 770 residues in size, with
a predicted mass of 88 kDa, whereas the major cellular
form of STAT3 (α) behaved as a 92 kDa polypeptide. A
splice variant of STAT3 encoding a shortened 80–83 kDa
form, STAT3β, has been identified. STAT3β lacks the car-
boxy terminal 55 amino acid residues of full-length
STAT3α protein and has seven novel amino acid residues
at its carboxy terminus [10,11]. While STAT3β has usually
been thought of as a dominant negative form on the basis
of its ability to block specific STAT3 functions when over-
expressed, recent studies have demonstrated that STAT3β
is not a dominant negative factor in vivo [12,13]. For
example, STAT3β seems to be the isoform involved in the
lipopolysaccharide-mediated induction of the inter-
leukin-10 (IL-10) promoter [13].
Subsequent studies identified a 72 kDa form of STAT3
(STAT3γ) which is activated in human neutrophils follow-
ing granulocyte colony-stimulating factor (G-CSF) treat-
ment. This STAT3γ is derived from limited proteolysis of
STAT3α, having lost a carboxy terminal portion of
STAT3α. This was predicted to yield a transcriptionally
inactive species which would still be competent for DNA-
binding [14]. Another short form of STAT3 was identified
in interleukin-1β (IL-1β)-treated insulin-secreting cells.
This IL-1β-inducible, carboxy terminal truncated 67 kDa
STAT3 species was shown to be a potent transcriptional
activator, in addition to retaining DNA-binding activity
[15]. A very recent study has reported that in several
human cell lines, induction of apoptosis led to a down-
regulation of full-length 92 kDa STAT3 in vivo [16]. While
incubating purified STAT3 in vitro with recombinant cas-
pases 1–10 was able to diminish the amount of full-length
STAT3 and led to the appearance of several species in the
50–70 kDa range which were immunologically reactive
with an antibody specific for the STAT3 amino terminus.
Interestingly, employing antibodies specific for the STAT3
carboxy terminus did not reveal the corresponding car-
boxy terminal fragments [16].
The present study reports that in wild type murine embry-
onic stem (ES) cells a significant proportion of the 92 kDa
STAT3α can be cleaved to yield an amino terminal species
of approximately 48 kDa and a carboxy terminal species
of approximately 43 kDa. The estimated position of the
STAT3α cleavage site corresponded closely with a poten-
tial cleavage site for the apoptotic caspase protease family
(DSGD, residues 371–374). Since STAT3 has anti-apop-
totic functions in a number of cellular systems [17-19]
this suggested that STAT3α might be a substrate for acti-
vated caspase proteases. We provide evidence for the
involvement of caspase proteases in this cleavage of
STAT3α, and the requirement for the JAK2-mediated tyro-
sine phosphorylation of residue Y705 to make STAT3α a
substrate for this cleavage. Since cleavage is enhanced in
differentiating ES cells, occurs also in breast cancer cells
that have high levels of constitutively active STAT3, and
occurs in vivo in normal murine mammary glands under-
going forced involution, this suggests that STAT3α cleav-
age may play an important role in modulating STAT3
transcriptional activity.
Methods
ES cell culture and treatments
IOUD2 ES cells (kindly provided by Austin Smith, Insti-
tute of Stem Cell Biology, University of Cambridge) and
HM-1 murine ES cells (passage 18) which are wild type
except for the targeted inactivation of both hypoxanthine
phosphoribosyl transferase (HPRT) alleles were cultured in
BHK-21 G-MEM medium (Gibco) supplemented with
10% 1:1 foetal bovine serum: newborn calf serum, 1 ×
MEM non-essential amino acids (Gibco), 1 mM sodium
pyruvate (Gibco), 2 mM L-glutamine (Gibco), 0.1 mM β-
mercaptoethanol, and leukaemia inhibitory factor (LIF)
(except where noted). To inhibit differentiation, HM-1
murine ES cells were plated on tissue culture plasticware
pre-coated with 0.1% gelatin solution. For HM-1 ES cell
treatment with the NO-donor sodium nitroprusside
(SNP) (Sigma), ES cell flasks were treated with the appro-
priate volume of 100 mM SNP stock solution and then
maintained in 5% CO2/37°C in the light for 2 hours
before harvesting. For ES cell treatment with AG490 (TCS
Biologicals, UK) and z-VAD-FMK (Bachem, Switzerland)
the inhibitors were dissolved in dimethylsulphoxide
(DMSO) (final DMSO concentration in the medium typ-
ically 0.5% vol/vol) and incubated with the cells in 5%
CO2/37°C for 18 hours prior to cell harvesting. The pro-
teasome inhibitor carbobenzoxyl-leu-leu-leucinal
(MG132) was added to a final concentration in the HM-1
ES cell medium of 10 µM or 50 µM in DMSO vehicle
(final DMSO concentration in the medium 0.2% vol/vol).BMC Cancer 2007, 7:29 http://www.biomedcentral.com/1471-2407/7/29
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For induction of apoptosis by UV irradiation, HM-1 ES
cells were irradiated (254 nm, 1 mJ/cm2) and harvested 13
hours later.
ES cell differentiation
IOUD2 murine ES cells were differentiated along either
the neural or adipocyte lineages. To direct ES cells to dif-
ferentiate along the neural lineage, 5 × 106 ES cells were
plated on gelatin coated tissue culture plastic dishes for 1
day in G-MEM medium (Sigma) supplemented with 10%
FetalClone III (HyClone), 1 × MEM non-essential amino
acids (Gibco), 1 mM sodium pyruvate (Gibco), 2 mM L-
glutamine (Gibco), 0.1 mM β-mercaptoethanol (Gibco)
plus LIF, then maintained in medium lacking LIF for 4
days, with the medium being changed daily. After 4 days,
1 µM all-trans retinoic acid (RA) (Sigma) was added to the
media for a further 4 days. Cells were maintained in dif-
ferentiation medium without RA from day 8 till day 20. At
10 days the differentiating cells were trypsinised and re-
plated onto tissue culture plasticware [20].
To induce the differentiation of IOUD2 ES cells along the
adipocyte lineage, 5 × 106 ES cells were plated on gelatin
coated tissue culture plasticware with cultivation medium
– G-MEM medium (Sigma) supplemented with 10%
FetalClone III (HyClone), 1 × MEM non-essential amino
acids (Gibco), 1 mM sodium pyruvate (Gibco), 2 mM L-
glutamine (Gibco), 0.1 mM β-mercaptoethanol (Gibco) –
and the cells maintained in this medium for 2 days.
Between days 2 and 5, the medium was supplemented
with RA to 1 µM, with the medium being changed daily.
At day 5, cells were switched to the G-MEM cultivation
medium, and from day 6 to day 20, cells were maintained
in cultivation medium supplemented with 85 nM insulin
and 2 nM tri-iodothyronine (T3) [21].
Breast cancer cell line culture
Human breast cancer cell lines MCF7, GI-101, T47H,
MDA-MB-231, MDA-MB-453, MDA-MB-468 and the nor-
mal breast cell line HB4A were cultured in D-MEM
medium (Gibco) supplemented with 10% foetal bovine
serum (Sigma). The MDA-MB-361 human breast cancer
cell line was cultured in a mixture of D-MEM and F12
media (Gibco) at a ratio of 50:50, supplemented with
10% foetal bovine serum and 10 µg/ml insulin (Sigma).
Forced involution and harvesting of murine mammary 
glands
Pregnant females were transferred to individual cages
prior to littering. If required, the size of the litter was
increased to 8 by cross-fostering equivalent aged pups. Lit-
ters were allowed to suckle for 10 days, then the litters
were removed, and the females either sacrificed immedi-
ately (by cervical dislocation) for 10 day lactation time-
points, or allowed to proceed to the 2, 3 and 6 day
involution timepoints. After harvesting, mammary glands
were immediately frozen in liquid nitrogen and then
stored at -80°C.
Extraction of cellular proteins
Proteins were extracted from combined adherent plus any
non-adherent ES cells by cell lysis in buffers containing
the non-ionic detergent Nonidet P40 (NP40). Early ES cell
experiments employed an initial low salt extraction of
cytoplasmic proteins followed by a high salt extraction of
the nuclei to recover nuclear DNA binding proteins. The
composition of the cytoplasmic extraction buffer was 25
mM Hepes. NaOH pH 7.5, 5 mM KCl, 0.5 mM MgCl2,
0.5% vol/vol NP40, 1 mM DL-dithiothreitol (DTT), 5 mM
disodium EDTA pH 8.0, 2 mM phenylmethylsulphonyl
fluoride (PMSF), 1 mM sodium metabisulphite, 1 mM
Na3VO4, 1 mM NaF, 1 µg/ml Antipain, 1 µg/ml Chy-
mostatin, 1 µg/ml Leupeptin, 1 µg/ml Pepstatin A
(Sigma). The high salt nuclear extraction buffer composi-
tion was similar but with the addition of NaCl to 400 mM.
Subsequent experiments used direct whole cell extraction
in the high salt (nuclear extraction) buffer. Protein con-
centrations for these extracts were determined by a modi-
fied Bradford assay (Bio-Rad Protein Assay).
For protein extraction of frozen mammary glands, a mod-
ified radioimmunoprecipitation (RIPA) buffer was
employed. Frozen glands were crushed twice to a fine
powder in liquid nitrogen, then extracted with 400 µl of
modified RIPA buffer (50 mM Tris.HCl pH 7.5, 150 mM
NaCl, 1% vol/vol NP40, 0.5% wt/vol sodium deoxycho-
late, 0.1% wt/vol sodium dodecyl sulphate (SDS), 1 mM
sodium orthovanadate, plus 1 protease inhibitor cocktail
tablet (Roche, Complete Mini) per 10 ml of RIPA buffer).
This mixture was then repeatedly sheared through a 25-
gauge hypodermic needle, centrifuged for 10 minutes at
10000 g at 4°C, and the resulting supernatant extract
recovered and aliquoted, then frozen in liquid nitrogen
and stored at -80°C. Protein concentrations of RIPA-type
extracts were determined using the Bio-Rad DC (Deter-
gent Compatible) protein assay system.
Immunoblotting analysis
Samples from cell extractions (typically containing 30 to
100 µg of protein) were resolved by sodium dodecyl sul-
phate polyacrylamide gel electrophoresis (SDS-PAGE) on
10% polyacrylamide gels (29:1 acrylamide:bisacrylamide
ratio) under reducing conditions (with the sample buffer
being supplemented with DTT to 100 mM) before transfer
by electroblotting to PVDF membranes (Immobilon P,
Millipore). The following primary antibodies were used at
the indicated dilutions for immunoblotting analysis.
Anti-carboxy-terminal STAT3 (Santa Cruz sc-482, 1:1000)
– specific for the STAT3α form; anti-amino-terminalBMC Cancer 2007, 7:29 http://www.biomedcentral.com/1471-2407/7/29
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STAT3 (BD/Transduction Laboratories S21320/610190,
1:1000); anti-total STAT3 (Cell Signaling Technology
#9132, 1:200) – epitope aa701–709. Anti-phosphotyro-
sine 705 STAT3 (Cell Signaling Technology #9131,
1:200); anti-PARP (BD/Pharmingen 556362, 1:1000);
anti-STAT1 (α+β) (Santa Cruz sc-346, 1:1000); anti-
STAT5 (a+b) (Santa Cruz sc-836, 1:1000) and anti-β-actin
(Sigma AC-74, 1:3000). Primary antibodies were diluted
in blocking buffer (tris-buffered saline (Sigma), 0.1%
Tween-20 (Sigma), 10% non-fat dried milk) and then
incubated with membranes overnight at 4°C. Horserad-
ish peroxidase-conjugated secondary antibodies (Amer-
sham GE Healthcare) were used at a 1:1000 dilution in
blocking buffer. ECL or ECL Plus chemiluminescent rea-
gents (Amersham GE Healthcare) and X-ray film (Hyper-
film ECL, Amersham GE Healthcare) were used to
visualise signals.
Results
STAT3α is cleaved into two fragments and cleavage is 
inhibited by the nitric oxide donor sodium nitroprusside
Immunoblots of HM-1 murine ES cell cytoplasmic
extracts with a polyclonal antibody (Santa Cruz, sc-482)
which recognises an epitope at the carboxy terminus of
the mouse STAT3α protein, revealed both the expected 92
kDa STAT3α species and another immunoreactive species
of approximately 43 kDa (Fig. 1A). To confirm that the 43
kDa immunoreactive species was STAT3α-derived, the
immunoblot was stripped and re-probed with an anti-
STAT3 polyclonal antibody (Cell Signaling Technology,
#9132) whose epitope is close to the Y705 residue and
also located within the carboxy terminal half of the mouse
STAT3 molecule (Fig. 1B).
To identify if the corresponding STAT3-derived amino ter-
minal species existed, the immunoblot was stripped and
re-probed with an anti-STAT3 monoclonal antibody
(Transduction Laboratories, S21320/610190) which rec-
ognises an epitope within the amino terminal first 175
amino acids of the mouse STAT3 protein. This antibody
detects both the full-length 92 kDa STAT3α protein and a
smaller species of approximately 48 kDa size (Fig. 1C).
Interestingly, the amounts of both the 43 kDa and 48 kDa
species could be influenced by treating the HM-1 ES cell
culture with the NO donor drug sodium nitroprusside
(SNP) which inhibits caspase activity [22] among other
targets. SNP reduced the amount of the 43 kDa and 48
kDa species in a dose-dependent way, suggesting that cas-
pases may play a role in the cleavage of STAT3 (Fig. 1A–C,
lanes 1–3, 6–8). In contrast, the addition of the proteas-
ome inhibitor, the peptide aldehyde MG132 (carboben-
zoxyl-leu-leu-leucinal) to the HM-1 ES cell culture at a 10
µM concentration (which blocks the proteasome-medi-
ated degradation of the Iκ Bα inhibitor of the transcrip-
tion factor NF-κB [23]) did not suppress the generation of
the 48 kDa and 43 kDa STAT3α cleavage products (Fig.
1A–C, lanes 4, 9) thus excluding the proteasome from
involvement in the cleavage of STAT3α. The presence or
absence of added LIF in the ES culture medium for 3 days
did not appreciably affect the extent of cleavage or its inhi-
bition by SNP (Fig. 1A–C, lanes 1–5 versus lanes 6–10).
Immunoblotting with a monoclonal antibody specific to
β-actin confirmed the equal amounts of protein loaded
per lane (Fig. 1D).
Interestingly, the relative amounts of the 48 kDa (amino
terminal) and 43 kDa (carboxy terminal) species remain
the same throughout these experimental treatments, sug-
gesting that they derive from a single proteolytic cleavage
event of the full-length STAT3α protein. Similar STAT3α
cleavage events were seen in the corresponding nuclear
extracts.
Within the murine STAT3α (and β) primary amino acid
sequence there are a number of potential cleavage sites for
members of the caspase family of cysteine proteases
which are involved in the effector phase of apoptotic pro-
grammed cell death [24], and which are increasingly rec-
ognised to be involved in cell differentiation. Three
potential DXXD-type caspase cleavage sites [25] are
located at residues 170–173 (DDFD), residues 184–187
(DMQD) and residues 371–374 (DSGD). Cleavage after
the second aspartic acid residue of the murine STAT3α
371–374 (DSGD) sequence would be consistent with the
observed cleavage product sizes.
Cleavage of STAT3α can be induced by UV radiation and 
correlates with JAK2 protein tyrosine kinase activity, 
phosphorylation of STAT3α residue Y 705 and caspase 
activity
As STAT3 has anti-apoptotic functions in a number of cel-
lular systems [17-19] we probed the effect of apoptotic
stimuli on ES cell cultures. UV irradiation of HM-1 ES cells
(254 nm, 1 mJ/cm2) and harvesting 13 hours later
revealed the cleavage of approximately 50% of the
STAT3α to yield the same size product in whole cell
extracts as detected previously with the anti-STAT3α car-
boxy terminal antibody (Santa Cruz, sc-482) (Fig. 2A,
lanes 3, 4). In contrast, the unirradiated control ES cells
showed little STAT3α cleavage in either the absence (-) or
presence (D) of 0.5% DMSO (vol/vol) in the medium
(Fig. 2A, lanes 1, 2).
To determine if caspase activity was required for the in
vitro cleavage of STAT3α, HM-1 ES cells were pre-incu-
bated with the pan-caspase inhibitor z-VAD-FMK (at final
concentrations in the medium of 1, 10 and 60 µM) for 18
hours prior to cell harvesting. Immunoblotting analysis of
whole cell extracts showed that z-VAD-FMK could inhibitBMC Cancer 2007, 7:29 http://www.biomedcentral.com/1471-2407/7/29
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Proteolytic cleavage of STAT3α in HM-1 murine ES cells to 48 kDa and 43 kDa fragments can be inhibited by the NO-donor  SNP Figure 1
Proteolytic cleavage of STAT3α in HM-1 murine ES cells to 48 kDa and 43 kDa fragments can be inhibited by the NO-donor 
SNP. A. An antibody (Santa Cruz sc-482) directed against amino acids 750–769 at the carboxy terminus of STAT3α revealed 
full-length STAT3α and a 43 kDa carboxy terminal cleavage product. 90 µg of protein were loaded per lane. B. Blot stripped 
and re-probed with an antibody (Cell Signaling Technology #9132) that recognises an epitope around the STAT3 Y705 residue 
within the carboxy terminal region, again detecting the 43 kDa cleavage fragment. C. Blot stripped and re-probed with an anti-
body that recognises an epitope within the STAT3 amino terminal amino acid 1–175 region (BD/Transduction Laboratories 
S21320/610190), detecting full-length STAT3α and a STAT3-derived 48 kDa amino terminal cleavage fragment. Cell culture 
treatment with the NO-donor (and caspase inhibitor) SNP for 2 hours reduced the level of the 43 kDa and 48 kDa fragments 
in a dose-dependent manner (lanes 1–3, 6–8 in panels A-C) in HM-1 ES cells cultured in either the presence (+LIF, lanes 1–5) 
or absence (-LIF, lanes 6y10) of added LIF in the medium. In contrast, the proteasome inhibitor MG132 added to 10 µM in the 
medium for 2 hours (with DMSO vehicle to a final concentration of 0.2% vol/vol) could not inhibit cleavage (lanes 4, 9 in A-C) 
relative to untreated cells, or DMSO vehicle alone (D). D. Blot stripped and re-probed with an anti β-Actin monoclonal anti-
body (Sigma, AC-74) to confirm equal amounts of protein loaded per lane.
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Modulation of STAT3α cleavage by caspase and JAK2 protein tyrosine kinase activity Figure 2
Modulation of STAT3α cleavage by caspase and JAK2 protein tyrosine kinase activity. A. Immunoblot showing a significant 
increase in STAT3α cleavage following UV irradiation. The Santa Cruz sc-482 antibody (recognising the carboxy terminus of 
STAT3α) revealed a significant increase in the level of the 43 kDa fragment following UV irradiation (+UV) of HM-1 ES cells 
(254 nm, 1 mJ/cm2, with harvesting 13 hours later) compared to control un-irradiated (-UV) cells in the presence (D) or 
absence (-) of 0.5% vol/vol DMSO vehicle, 100 µg of whole cell extract protein loaded per lane. B. Immunoblot demonstrating 
dose-dependent inhibition of STAT3α cleavage by the pan-caspase inhibitor z-VAD-FMK and the JAK2 tyrosine kinase inhibitor 
AG490. The 43 and 48 kDa STAT3α fragments were essentially abolished by pretreating HM-1 ES cells with z-VAD-FMK to 60 
µM (lanes 1, 2, 6–8, C-term. STAT3α and N-term. STAT3 panels) or AG490 to 250 µM (lanes 1–5, C-term. STAT3α and N-
term. STAT3 panels) for 18 hours in the cell culture medium before harvesting. The 250 µM AG490-mediated abolition of 
STAT3α cleavage correlated with loss of tyrosine phosphorylation of the STAT3α Y705 residue (lane 5, PY 705 STAT3 panel). 
75 µg of whole cell extract protein loaded per lane, DMSO added to 0.5% vol/vol in the culture medium in the z-VAD-FMK 
and AG490 treatments and the DMSO control (D). C. Identical behaviour of HM-1 ES cell cytoplasmic and nuclear extracts 
following AG490-mediated inhibition of STAT3α cleavage and inability of 50 µM MG132 to inhibit STAT3α cleavage. 100 µg of 
cytoplasmic or nuclear extract protein loaded per lane, DMSO added to 1% vol/vol in the culture medium for AG490 and 
MG132 treatments and DMSO controls (D), treatments given for 7 hours prior to cell harvesting. Immunoblots used the Santa 
Cruz sc-482 antibody. D. Down-regulation of STAT3α cleavage in JAK2 heterozygous knockout (JAK2 +/-) ES cells. Wild type 
HM-1 and JAK2 +/- ES cells were cultured with (+LIF) or without (-LIF) added LIF for 3 days prior to harvesting. Cytoplasmic 
extracts (100 µg protein per lane) were immunoblotted with the Santa Cruz sc-482 antibody. E. Immunoblots of RIPA extracts 
of wild type (W.T.) and SMAD4 transgenic (+) murine mammary glands from day 10 lactation (D10L) and 2 day (D2In.), 3 day 
(D3In.) and 6 day (D6In.) forced involution timepoints showing the close linkage between appearance of tyrosine 705 phospho-
rylated STAT3α and the generation of the 43 kDa carboxy terminal STAT3α cleavage product. 20 µg of RIPA whole cell 
extract protein was loaded per lane.
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STAT3α cleavage in a dose-dependent manner, with the
generation of the 43 kDa and 48 kDa carboxyl- and
amino-terminal fragments essentially abolished in the
presence of 60 µM z-VAD-FMK (Fig. 2B, lanes 1, 2, 6–8, C-
terminal STAT3α and N-terminal STAT3 panels). Interest-
ingly, the JAK2 tyrosine kinase inhibitor AG490 was also
able to inhibit STAT3α cleavage in a dose-dependent
manner (Fig. 2B, lanes 1–5, C-terminal STAT3α and N-ter-
minal STAT3 panels) – this STAT3α cleavage inhibition
correlated with the down-regulation of phosphorylation
of STAT3α residue Y 705 (Fig. 2B, lanes 1–5, PY 705
STAT3 panel), consistent with STAT3 being a known tar-
get for tyrosine phosphorylation by JAK2 [26].
In contrast to these dramatic changes in the behaviour of
STAT3α, there were no major changes in the behaviour of
STAT1 (α+β) or STAT5 (a+b) (Fig. 2B, STAT1 and STAT5
panels) in response to the above treatments. One interest-
ing point was the presence of a low level of PARP cleavage
in the HM-1 ES cell cultures which was greatly up-regu-
lated in response to AG490 treatment – consistent with
earlier reports that AG490 treatment can induce apoptosis
(Fig. 2B, lanes 1–5, PARP panel).
Comparing separate cytoplasmic and nuclear extracts of
AG490-treated HM-1 ES cells revealed no differences in
the AG490-mediated inhibition of the STAT3α cleavage
event, nor could the MG132 proteasome inhibitor inhibit
the cleavage event, even at an elevated 50 µM concentra-
tion in the culture medium (Fig. 2C). Furthermore, in het-
erozygous  JAK2  knockout ES cell clone cytoplasmic
extracts (JAK2 +/-) there were lower levels of the STAT3α
cleavage than in wild type (W.T.) ES cell cytoplasmic
extracts, either when cultured in the presence (+LIF) or
absence (-LIF) of LIF for 3 days (Fig. 2D).
To confirm the in vivo relevance of this cleavage event, the
murine mammary gland was chosen as a model system –
this can be made to undergo a forced involution where
large scale apoptosis occurs in the secretory epithelium.
Also, it is known from previous studies that STAT3 is tran-
siently tyrosine phosphorylated and activated during this
forced involution process [27]. Whole cell RIPA-type
extracts were prepared from day 10 of lactation (D10L)
and days 2 (D2In.), 3 (D3In.) and 6 (D6In.) of involution
mammary glands from wild type (W.T.) and SMAD4
transgenic mice (+). When these extracts were analysed by
immunoblotting, there was a dramatic up-regulation of
STAT3α cleavage during forced involution – reaching a
maximum around day 3 of involution for wild type mice
(Fig. 2E, C-terminus STAT3α panel). This peak in STAT3α
cleavage coincided with a peak in STAT3α tyrosine 705
phosphorylation (Fig. 2E, PY 705 STAT3 panel). Similar
behaviour was observed in extracts from SMAD4 trans-
genic mammary glands. Most interestingly, the tyrosine
phosphorylation and STAT3α cleavage events observed
around days 2 and 3 of involution were also associated
with the appearance of high molecular weight smears
above the position of full-length STAT3α. The above lines
of evidence suggest that JAK2 tyrosine kinase activity, with
the resultant phosphorylation of STAT3α residue Y 705 is
necessary to allow STAT3α to become a substrate for a cas-
pase-dependent proteolytic cleavage.
STAT3α cleavage during ES cell differentiation
STAT3 is required for the self renewal of ES cells. However,
STAT3 is also active during ES cell differentiation. Nota-
bly, upon the removal of LIF for up to 3 days (Fig. 3A), the
extent of STAT3 cleavage in IOUD2 ES cells to the 48 kDa
amino-terminal fragment increases in concert with a
decline in the amount of full length STAT3α.
We next investigated whether this cleavage is affected by
the lineage taken during ES cell differentiation. During a
time course of specific differentiation along the neural
and adipocyte cell lineages, STAT3α is cleaved to produce
the 43 kDa and 48 kDa fragments (Fig. 3B and 3C). This
processing is particularly striking in the neural lineage dif-
ferentiation where full length 92 kDa STAT3α is dramati-
cally down-regulated at days 8 and 10, yielding high levels
of both fragments. It is also interesting to note that the
extent of cleavage differs between the two cell lineages,
with a smaller proportion of total STAT3α being cleaved
in the adipocytes. The cleavage of STAT3α is clearly regu-
lated during differentiation, suggesting that either the
cleavage products have lineage-specific functions or that
cleavage is an alternative mechanism of regulating
STAT3α transcriptional activity.
Cleavage of STAT3 in breast cancer cell lines
STAT3 has been shown to be a pro-apoptotic factor in the
involuting mammary gland [27]. Paradoxically, is also
constitutively active in a number of breast cancers and in
breast cancer cell lines [28]. In order to determine whether
caspase-dependent cleavage of human STAT3α occurs in
breast cancer, we carried out immunoblot analysis of 1
normal breast line and 7 breast cancer cell lines with var-
ying levels of tyrosine phosphorylated STAT3 (Fig. 4, PY
705 STAT3 panel). STAT3α cleavage was highest in GI-101
cells and lowest in MCF-7 cells that have an inactive cas-
pase-3. The extent of cleavage correlated approximately
with the amount of tyrosine phosphorylated STAT3α
except for the normal line HB4A where the cleaved frag-
ments were undetectable. Longer exposure revealed an
additional cleaved STAT3 fragment of 25 kDa that is
detected by the amino-terminal antibody. This fragment
size would be consistent with cleavage at the caspase 3
consensus site at amino acid 187 (DMQD) and we suggest
that this cleavage event is subsequent to the one around
the caspase consensus site at amino acid 374 (DSGD),BMC Cancer 2007, 7:29 http://www.biomedcentral.com/1471-2407/7/29
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STAT3 cleavage during ES cell differentiation along neural or adipocyte cell lineages Figure 3
STAT3 cleavage during ES cell differentiation along neural or adipocyte cell lineages. A. Short term differentiation of murine 
IOUD2 ES cells following removal of LIF for 48 hours. In the adipocyte differentiation protocol, cells were treated with RA 
between 48 and 72 hours, while cells differentiating along the neural lineage were untreated. Whole cell extracts were immu-
noblotted with either the anti-STAT3 amino terminal antibody (upper panel, 48 kDa cleaved fragment) or the anti-STAT3 
PY705 antibody (lower panel, 43 kDa cleaved fragment). B. 20 day differentiation time course of IOUD2 ES cells along the neu-
ral cell lineage. Cells were harvested at the indicated timepoints and whole cell extracts immunoblotted with either the anti-
STAT3 amino terminal antibody (upper panel, 48 kDa cleaved fragment) or the anti-STAT3 PY705 antibody (lower panel, 43 
kDa cleaved fragment). C. 20 day differentiation time course of IOUD2 ES cells along the adipocyte cell lineage. Cells were 
harvested at the indicated timepoints and whole cell extracts immunoblotted with either the anti-STAT3 amino terminal anti-
body (upper panel, 48 kDa cleaved fragment) or the anti-STAT3 PY705 antibody (lower panel, 43 kDa cleaved fragment). 
Arrows indicate cleaved fragments and the asterisk non-specific bands.
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since otherwise the 48 kDa fragment would not be appar-
ent.
Discussion
Tyrosine phosphorylation and dephosphorylation allows
a rapid and reversible control of STAT activity, however
there may be situations in which a more long term or per-
manent loss of STAT biological activity is required. The
cleavage of tyrosine phosphorylated STAT3α within the
region involved in making specific DNA contacts could
allow its sustained inactivation, which could be required
during apoptotic death or during stem cell differentiation.
The caspase-dependent proteolytic cleavage of tyrosine
phosphorylated STAT3α reported here is likely to differ
from other systems where the STAT3 cleavage product
retains DNA binding and, in some cases, transcriptional
activation functions. It is also very different from a study
in human neuroblastoma cells which suggested that treat-
ment with ciliary neurotrophic factor or a phorbol ester
Cleavage of STAT3α in human breast cancer cell lines Figure 4
Cleavage of STAT3α in human breast cancer cell lines. Whole cell extracts from one normal human breast cell line (HB4A) and 
7 breast cancer cell lines with varying levels of activated, tyrosine phosphorylated, STAT3α were immunoblotted with either 
the anti-STAT3 amino terminal antibody (upper panel, 48 kDa cleaved fragment) or the anti-STAT3 PY705 antibody (lower 
panel, 43 kDa cleaved fragment). Over exposure of the upper blot revealed an additional cleavage product of approximately 25 
kDa that was most apparent in the GI-101 cell line which has the highest level of tyrosine phosphorylated STAT3α in the 
breast cancer cell lines examined. Extracts from C57Bl/6 mouse mammary glands were loaded as controls: 5d Gest = day 5 
pregnancy; 10d Lac = 10 days of lactation; 96 Hr In = 96 hours following forced weaning at day 10 lactation. Arrows indicate 
cleaved fragments.
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could induce a proteasome-dependent degradation of
STAT3 which could be inhibited by MG132 and in which
no discrete cleavage products were reported [29].
In support of the current study showing the caspase-
dependency of STAT3α cleavage, the STAT1 family mem-
ber has been shown to be a direct substrate for caspases
following the induction of apoptosis by double-stranded
RNA [30]. It was thought that this cleavage event might
alter cellular ability to respond to apoptotic stimuli. The
executioner caspases, caspases 3, 6 and 7, are primarily
involved in apoptosis although there is mounting evi-
dence for additional roles for these caspases in differenti-
ation [31]. The caspases involved and their function
during differentiation is cell type dependent – caspase 3 is
activated in terminally differentiated rodent lens epithe-
lial cells [32], while caspases 3 and 9 bring about an arrest
in erythroid differentiation via cleavage of GATA1 [33].
Caspases 3 and 9 are also active in human peripheral
blood monocytes induced to differentiate into macro-
phages – this activation was not seen in monocyte differ-
entiation into dendritic cells and therefore was cell type
specific [34]. Caspase 3 activity has recently also been
shown to be involved in skeletal muscle differentiation
[35]. Although the exact functions of non-apoptotic cas-
pase activity remain unclear, it seems increasingly likely
that they can play critical roles in cellular proliferation
and differentiation. This caspase-dependent STAT3α
cleavage could join a growing list of substrates cleaved
during differentiation and apoptosis.
There are precedents for phosphorylation status affecting
the susceptibility of a substrate protein towards caspase-
mediated cleavage. For example, serine phosphorylation
of the chicken Iκ Bα inhibitor protein at residues 36 and
40 prevented cleavage by caspase 3 after residue 35, which
might otherwise generate a constitutive, non-degradable,
inhibitor molecule [36].
Given the close correspondence between the cleavage site
and the putative caspase site (residues 371–374), STAT3α
cleavage might be mediated directly by an activated cas-
pase. Cleavage could require tyrosine phosphorylated
STAT3α to be present in a STAT dimer bound to its specific
DNA motif before the caspase cleavage site becomes
accessible through some conformational change. There is
at least one precedent for the modification of the sensitiv-
ity of a caspase substrate towards cleavage when bound to
DNA – a study of poly-(ADP-ribose) polymerase (PARP)
susceptibility to cleavage by caspase 3 showing that when
PARP was bound to DNA, its rate of cleavage was greatly
reduced [37].
This caspase-dependent cleavage of tyrosine phosphor-
ylated STAT3α might represent an early stage during
apoptosis with the cleavage of a factor which usually per-
forms anti-apoptotic functions. It is also possible that, as
STAT3 activity is needed for the self-renewal of murine ES
cells [38], cleavage might reflect a low level of differentia-
tion among the ES cells. This is supported by our data
showing that during differentiation, cleavage of STAT3α is
more extensive. The additional cleavage observed in
breast cancer cell lines close to a consensus caspase 3
cleavage site to generate a 25 kDa amino terminal frag-
ment, could be a mechanism to decrease the level of con-
stitutively active STAT3 in these cells. Since STAT3 is
normally a transiently activated pro-apoptotic factor in
mammary epithelial cells undergoing forced involution
[27], the constitutive activation of STAT3 in breast cancers
[28] and its role as an oncogene [39] is an apparent para-
dox. Caspase-dependent cleavage of this tyrosine phos-
phorylated STAT3α might reduce the levels of STAT3
activity and it is noteworthy that the extent of cleavage is
related to the level of full-length tyrosine phosphorylated
STAT3α.
It seems plausible that in some mammary cancers there is
a failure to properly engage the apoptotic machinery –
leading to an inappropriate prolonged activation of
STAT3α. The failure of a normally transient STAT3α acti-
vation to be down-regulated by cleavage might allow the
continued expression of genes such as Bcl-xL – conferring
continued resistance to apoptosis in the mammary epithe-
lium. This inappropriate retention of epithelial tissue
might be a mechanism predisposing to mammary tumour
development.
Conclusion
This study documents a proteolytic cleavage of STAT3α
into 48 kDa amino-terminal and 43 kDa carboxy-terminal
fragments in murine ES cells (both undifferentiated and
differentiating), in murine mammary glands undergoing
forced involution and in human breast cancer cells. The
STAT3α cleavage could be inhibited dose-dependently by
the NO-donor SNP. The extent of STAT3α cleavage corre-
lated with the level of phosphorylation of the Y705 resi-
due, cleavage could be inhibited by the JAK2 protein
tyrosine kinase inhibitor AG490, and was significantly
lower in a JAK2 heterozygous knockout ES clone. UV irra-
diation of ES cells induced STAT3α cleavage, suggesting
the involvement of apoptotic caspase proteases – interest-
ingly, the estimated cleavage site location corresponded
closely to a potential caspase 3 cleavage site (DSGD, resi-
dues 371–374) located in the STAT3 DNA-binding
domain. STAT3α cleavage could also be inhibited dose-
dependently by the pan-caspase inhibitor z-VAD-FMK.
We suggest that STAT3α when phosphorylated at the
Y705 residue can undergo a caspase-dependent proteo-
lytic cleavage close to a potential caspase site at residues
371–374 (DSGD). We also suggest that this highly regu-
lated cleavage may have an important role in modulating
STAT3 transcriptional activity.BMC Cancer 2007, 7:29 http://www.biomedcentral.com/1471-2407/7/29
Page 11 of 12
(page number not for citation purposes)
Abbreviations
DMSO, dimethylsulphoxide; DTT, DL-dithiothreitol;
EDTA, ethylenediaminetetraacetic acid; ES, embryonic
stem; G-CSF, granulocyte colony-stimulating factor; IL-
1β, interleukin-1β; JAK, Janus kinase; LIF, leukaemia
inhibitory factor; MG132, carbobenzoxyl-leu-leu-leuci-
nal; NO, nitric oxide; NP40, Nonidet P40; PARP, poly-
(ADP-ribose) polymerase; PMSF, phenylmethylsulphonyl
fluoride; PVDF, polyvinylidene difluoride; RA, all-trans
retinoic acid; RIPA, radioimmunoprecipitation; SDS,
sodium dodecyl sulphate; SDS-PAGE, sodium dodecyl
sulphate polyacrylamide gel electrophoresis; SNP, sodium
nitroprusside; STAT, signal transducer and activator of
transcription; z-VAD-FMK, z-Val-Ala-DL-Asp-fluorometh-
ylketone.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
JRM, SMRW and MCLT carried out the tissue culture and
immunoblotting analysis. JRM conceived the study. JRM,
SMRW, MCLT, CJW and ARC drafted the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by the UK Biotechnology and Biological Sciences 
Research Council and the AICR. We thank Dr. Stefan Selbert for supplying 
the heterozygous JAK2 knockout ES cell clone and thank Professor Austin 
Smith for supplying IOUD2 ES cells.
References
1. Darnell JE Jr: STATs and gene regulation.  Science 1997,
277:1630-1635.
2. Ihle JN: STATs: Signal transducers and activators of tran-
scription.  Cell 1996, 84:331-334.
3. O'Shea JJ: Jaks, STATs, Cytokine signal transduction and
immunoregulation: are we there yet?  Immunity 1997, 7:1-11.
4. Levy DE, Darnell JE Jr: STATs: Transcriptional control and bio-
logical impact.  Nat Rev Mol Cell Biol 2002, 3:651-662.
5. Yu H, Jove R: The STATs of cancer – new molecular targets
come of age.  Nat Rev Cancer 2004, 4:97-105.
6. Philp JA, Burdon TG, Watson CJ: Differential activation of
STATs 3 and 5 during mammary gland development.  FEBS
Lett 1996, 396:77-80.
7. Zhong Z, Wen Z, Darnell JE Jr: Stat3: A STAT family member
activated by tyrosine phosphorylation in response to epider-
mal growth factor and interleukin-6.  Science 1994, 264:95-98.
8. Zhong Z, Wen Z, Darnell JE Jr: Stat3 and Stat4: Members of the
family of signal transducers and activators of transcription.
Proc Natl Acad Sci USA 1994, 91:4806-4810.
9. Akira S, Nishio Y, Inoue M, Wang X-J, Wei S, Matsusaka T, Yoshida
K, Sudo T, Naruto M, Kishimoto T: Molecular cloning of APRF, a
novel IFN-stimulated gene factor 3 p91-related transcription
factor involved in the gp130-mediated signalling pathway.
Cell 1994, 77:63-71.
10. Schaefer TS, Sanders LK, Nathans D: Cooperative transcriptional
activity of Jun and Stat3β, a short form of Stat3.  Proc Natl Acad
Sci USA 1995, 92:9097-9101.
11. Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JAM,
Lammers JWJ, Koenderman L, deGroot RP: STAT3β A splice var-
iant of transcription factor STAT3, is a dominant negative
regulator of transcription.  J Biol Chem 1996, 271:13221-13227.
12. Yoo J-Y, Huso DL, Nathans D, Desiderio S: Specific ablation of
Stat3β distorts the pattern of Stat3-responsive gene expres-
sion and impairs recovery from endotoxic shock.  Cell 2002,
108:331-344.
13. Maritano D, Sugrue ML, Tininini S, Dewilde S, Strobl B, Fu X, Murray-
Tait V, Chiarle R, Poli V: The STAT3 isoforms α and β have
unique and specific functions.  Nat Immunol 2004, 5:401-409.
14. Chakraborty A, Tweardy DJ: Granulocyte colony-stimulating
factor activates a 72-kDa isoform of STAT3 in human neu-
trophils.  J Leukocyte Biol 1998, 64:675-680.
15. Morton NM, de Groot RP, Cawthorne MA, Emilsson V: Interleukin-
1β activates a short STAT-3 isoform in clonal insulin-secret-
ing cells.  FEBS Lett 1999, 442:57-60.
16. Darnowski JW, Goulette FA, Guan Y-J, Chatterjee D, Yang Z-, Cous-
ens L-P, Chin Y-E: Stat3 Cleavage by caspase. Impact on full-
length Stat3 expression, fragment formation, and transcrip-
tional activity.  J Biol Chem 2006, 281:17707-17717.
17. Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y,
Yamaguchi T, Nakajima K, Hirano T: Two signals are necessary
for cell proliferation induced by a cytokine receptor gp130:
involvement of STAT3 in anti-apoptosis.  Immunity 1996,
5:449-460.
18. Bellido T, O'Brien CA, Roberson PK, Manolagas SC: Transcrip-
tional activation of the p21Waf1, CIP1, SDI1 gene by interleukin-
6 type cytokines.  J Biol Chem 1998, 273:21137-21144.
19. Takeda K, Kaisho T, Yoshida N, Taskeda J, Kishimoto T, Akira S:
Stat3 Activation is responsible for IL-6 dependent T cell pro-
liferation through preventing apoptosis: generation and
characterization of T cell-specific Stat3-deficient mice.  J
Immunol 1998, 161:4652-4660.
20. Ward CM, Barrow KM, Stern PL: Significant variations in differ-
entiation properties between independent mouse ES cell
lines cultured under defined conditions.  Exp Cell Res 2004,
293:229-238.
21. Dani C, Smith AG, Dessolin S, Leroy P, Staccini L, Villageois P, Dari-
mont C, Ailhaud G: Differentiation of embryonic stem cells
into adipocytes in vitro.  J Cell Sci 1997, 110:1279-1285.
22. Dimmeler S, Haendeler J, Nehls M, Zeiher AM: Suppression of
apoptosis by nitric oxide via inhibition of interleukin-1β-con-
verting enzyme (ICE)-like and cysteine protease protein
(CPP)-32-like proteases.  J Exp Med 1997, 185:601-608.
23. Roff M, Thomson J, Rodriguez MS, Jacque J-M, Baleux F, Arenzana-
Seisdedos F, Hay RT: Role of I kappa B alpha ubiquitination in
signal-induced activation of NF-kappa B in vivo.  J Biol Chem
1996, 271:7844-7850.
24. Dost B, Wyllie AH: ICE-like proteases and cell death.  Behring
Inst Mitt 1996, 97:127-143.
25. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Gar-
cia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP,
Chapman KT, Nicholson DW: A combinatorial approach defines
specificities of members of the caspase family and granzyme
B.  J Biol Chem 1997, 272:17907-17911.
26. Brizzi MF, Aronica MG, Rosso A, Bagnara GP, Yarden Y, Pegoraro L:
Granulocyte-macrophage colony-stimulating factor stimu-
lates JAK2 signaling pathway and rapidly activates p93,
STAT1 p91, and STAT3 p92 in polymorphonuclear leuko-
cytes.  J Biol Chem 1996, 271:3562-3567.
27. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K,
Akira S, Clarke AR, Watson CJ: Suppression of epithelial apop-
tosis and delayed mammary gland involution in mice with a
conditional knockout of Stat3.  Genes Dev 1999, 13:2604-2616.
28. Watson CJ, Miller WR: Elevated levels of members of the
STAT family of transcription factors in breast carcinoma
nuclear extracts.  Brit J Cancer 1995, 71:840-844.
29. Malek RL, Halvorsen SW: Ciliary neurotrophic factor and phor-
bol ester each decrease selected STAT3 pools in neuroblas-
toma cells by proteasome-dependent mechanisms.  Cytokine
1999, 11:192-199.
30. King P, Goodbourn S: STAT1 is inactivated by a caspase.  J Biol
Chem 1998, 273:8699-8704.
31. Schwerk C, Schulze-Osthoff K: Non-apoptotic functions of cas-
pases in cellular proliferation and differentiation.  Biochem
Pharmacol 2003, 66:1453-1458.
32. Ishizaki Y, Jacobson MD, Raff MC: Role for caspases in lens fiber
differentiation.  J Cell Biol 1998, 140:153-158.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2007, 7:29 http://www.biomedcentral.com/1471-2407/7/29
Page 12 of 12
(page number not for citation purposes)
33. De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani
F, Srinivasula SM, Alnemri ES, Testa U, Peschle C: Negative regula-
tion of erythropoiesis by caspase-mediated cleavage of
GATA-1.  Nature 1999, 401:489-493.
34. Sordet O, Rebe C, Plenchette S, Zermati Y, Hermine O, Vainchenker
W, Garrido C, Solary E, Dubrez-Daloz L: Specific involvement of
caspases in the differentiation of monocytes into macro-
phages.  Blood 2002, 100:4446-4453.
35. Fernando P, Kelly JF, Balazsi K, Slack RS, Megeney LA: Caspase 3
activity is required for skeletal muscle differentiation.  Proc
Natl Acad Sci USA 2002, 99:11025-11030.
36. Barkett M, Xue D, Horvitz HR, Gilmore TD: Phosphorylation of Iκ
Bα inhibits its cleavage by caspase CPP32 in vitro.  J Biol Chem
1997, 272:29419-29422.
37. D'Amours D, Germain M, Orth K, Dixit VM, Poirier GG: Proteoly-
sis of poly(ADP-ribose)polymerase by caspase 3: kinetics of
cleavage of mono(ADP-ribosyl)ated and DNA-bound sub-
strates.  Radiation Res 1998, 150:3-10.
38. Niwa H, Burdon T, Chambers I, Smith A: Self-renewal of pluripo-
tent embryonic stem cells is mediated via activation of
STAT3.  Genes Dev 1998, 12:2048-2060.
39. Bromberg JF, Wrzeszczynska MH, Devgan G, Xhao YX, Pestell RG,
Albanese C, Darnell JE Jr: Stat3 As an oncogene.  Cell 1999,
98:295-303.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/29/prepub